This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?
4/28/16 1:30PM
Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.
4/28/16 10:17AM
Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.
4/27/16 5:03PM
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.
4/27/16 7:35AM
An advisory committee convened by the U.S. Food and Drug Administration is reviewing Sarepta's experimental Duchenne muscular dystrophy drug.
4/25/16 7:34AM
The FDA advisory panel review of Sarepta's DMD drug eteplirsen will be surprising, controversial, volatile, dramatic, newsworthy and memorable.
4/24/16 12:46PM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
4/22/16 8:31AM
The news was still negative for eteplirsen, the Duchenne muscular dystrophy drug from Sarepta Therapeutics.
4/21/16 9:58AM
Efforts by insurers to negotiate higher discounts or rebates on specialty pharmaceutical products isn't keeping pace with the price increases pushed through by drug and biotech companies, an analyst says.
4/20/16 10:10AM
Bluebird is trying to use a gene therapy to correct the rare and fatal genetic defect found in boys with CALD.
4/20/16 8:31AM
Chiasma shares are plunging Monday following the U.S. Food and Drug Administration rejection of the company's drug to treat acromegaly, a rare disease of the pituitary gland.
4/18/16 8:46AM
Six patients, all with TRK fusion cancers unresponsive to current therapies, reported tumor shrinkage following treatment with Loxo's drug LOXO-101.
4/17/16 5:17PM
TheStreet's Adam Feuerstein answers reader questions about biotech investing. There were a high number of emails on the upcoming Sarepta FDA advisory panel.
4/15/16 6:00AM
Chiasma is expecting the U.S. Food and Drug Administration to make an approval decision Friday on a new oral treatment for acromegaly, a rare disease of the pituitary gland.
4/14/16 7:50AM
An FDA advisory committee delivers a brutal beatdown of Clovis' lung cancer drug rociletinib. It could cost Clovis' CEO his job.
4/12/16 1:51PM
Investors give the side eye to a prediction from Chardan analyst Gbola Amusa that Amicus Therapeutics will be acquired for three times its current market value
4/12/16 12:21PM
Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.
4/12/16 7:00AM
Shares of Endo fall as much as 9% Monday in sympathy with Insys Therapeutics, which pre-announced sharply weaker first-quarter sales of its fentanyl painkiller Subsys.
4/11/16 1:11PM
Now that the Allergan-Pfizer merger is off, Allergan CEO Saunders could start shopping again for biotech and smaller pharma companies to fuel his company's growth.
4/10/16 10:00AM
Clovis Oncology is better off if the U.S. Food and Drug Administration rejects its lung cancer drug rociletinib.
4/8/16 10:28AM
Relypsa has hired an investment bank and is exploring a sale following the receipt of offers from a "number of potential buyers," Reuters reports.
4/7/16 1:55PM
Both Allergan and Pfizer could target biotech and drug company acquisitions as a way to fuel future growth.
4/6/16 11:06AM
The extravagant travel-expense payouts to Provectus CEO Craig leaves the company at risk of criminal or civil investigations by the Securities and Exchange Commission.
4/5/16 11:25AM
Vertex's stock price has been cut almost in half since the cystic fibrosis drug Orkambi launched last summer.
4/4/16 11:54AM

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%
Top Rated Stocks Top Rated Funds Top Rated ETFs